gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Cytotoxic T-lymphocyte-associated protein 4

CTLA-4, CD152
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, CD4, PD-L1, Foxp3, HAD
Papers using CTLA-4 antibodies
IFN-g production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo
Zheng Song Guo, In PLoS ONE, 2004
... anti-CD123 (9F5, BD Biosciences), anti-CD127 (HIL-7R-M21, BD Pharmingen), anti-CD303 (AC144, Miltenyi Biotec), anti-Foxp3 (259D, eBioscience), anti-CTLA-4 (BNI3, BD Biosciences).
Contact-dependent Stimulation and Inhibition of Dendritic Cells by Natural Killer Cells
Valiante Nicholas M. et al., In The Journal of Experimental Medicine, 1995
... sheep polyclonal anti–human; Ancell); anti–IFN-β (sheep polyclonal anti–human; Biosource International); r-hu-fas-ligand/Fc chimera (CD178; R&D Systems); hu-CTLA-4 muIg fusion protein (CD152; Ancell); anti–LFA-1 (CD11a, mAb G43–25B; ...
Papers on CTLA-4
Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy.
Smyth et al., Hannover, Germany. In Cancer Discov, Feb 2016
Anti-CD96 was more effective in combination with anti-CTLA4, anti-PD1 or doxorubicin chemotherapy.
Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease.
Carbonnel et al., Clamart, France. In J Crohns Colitis, Feb 2016
BACKGROUND: Therapeutic monoclonal anti-CTLA-4-antibodies are associated with immune-mediated enterocolitis.
The immune system and cancer evasion strategies: therapeutic concepts.
Hoeller et al., Basel, Switzerland. In J Intern Med, Feb 2016
Finally, we will focus on therapies that are already used in daily oncological practice such as the blockade of immune checkpoints cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) in patients with metastatic melanoma or advanced lung cancer, or therapies currently being tested in clinical trials such as adoptive T-cell transfer.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Lambotte et al., Villejuif, France. In Eur J Cancer, Feb 2016
The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its ligand PD-L1.
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
DeGregorio et al., Sacramento, United States. In Ther Adv Med Oncol, Jan 2016
The clinical success of monoclonal antibody immune checkpoint modulators such as ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the recently approved agents nivolumab and pembrolizumab, which target programmed cell death receptor 1 (PD-1), has stimulated renewed enthusiasm for anticancer immunotherapy, which was heralded by Science as 'Breakthrough of the Year' in 2013.
Management of Immune Checkpoint Blockade Dysimmune Toxicities: a collaborative position paper.
Marabelle et al., Villejuif, France. In Ann Oncol, Jan 2016
UNASSIGNED: Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non-small cell lung cancers.
Genomics of Immune Diseases and New Therapies.
Lucas et al., Bethesda, United States. In Annu Rev Immunol, Jan 2016
At the end, we discuss two other recently described diseases, PASLI (PI3K dysregulation) and CHAI/LATAIE (CTLA-4 deficiency), as additional examples of the journey from unknown immunological diseases to new precision medicine treatments using genomics.
Updates in Therapy for Advanced Melanoma.
Salama et al., Durham, United States. In Cancers (basel), Dec 2015
The successful targeting of CTLA-4, as well as PD-1/PD-L1, has been translated into meaningful clinical benefit for patients, with multiple other potential agents in development.
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.
Wallberg et al., Cambridge, United Kingdom. In Plos One, Dec 2015
Further, we demonstrate that combination treatment with CTLA4-Ig does not improve the efficacy of treatment, but instead attenuates the protective effects seen with CTLA4-Ig treatment alone.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Zitvogel et al., Villejuif, France. In Science, Dec 2015
Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy.
Integrated molecular analysis of adult T cell leukemia/lymphoma.
Ogawa et al., Kyoto, Japan. In Nat Genet, Nov 2015
Other notable features include a predominance of activating mutations (in PLCG1, PRKCB, CARD11, VAV1, IRF4, FYN, CCR4 and CCR7) and gene fusions (CTLA4-CD28 and ICOS-CD28).
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Garraway et al., Boston, United States. In Science, Nov 2015
Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic melanoma by inhibiting immune checkpoint activity, but clinical predictors of response to these therapies remain incompletely characterized.
Releasing the Brakes on Cancer Immunotherapy.
Littman, New York City, United States. In Cell, Oct 2015
This year's Lasker∼DeBakey Clinical Research Award goes to James Allison for discovering that antibody blockade of the T cell molecule CTLA-4 unleashes the body's immune response against malignant tumors.
Association of TNF-α, CTLA4, and PTPN22 polymorphisms with type 1 diabetes and other autoimmune diseases in Brazil.
Brandão et al., Recife, Brazil. In Genet Mol Res, 2014
Polymorphisms in the TNF-α(rs1800629), CTLA-4 (rs231775), and PTPN22 (rs2476601) genes have been previous associated with T1D; however, there is no consensus regarding their role in T1D and scarce literature focusing on AIDT and/or CD.
Association between PDCD1, CTLA4, and MECP2 gene polymorphisms and systemic lupus erythematosus in the Chinese Northern Han.
Chang et al., Hohhot, China. In Genet Mol Res, 2014
The programmed cell death 1 gene (PDCD1), the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) gene, and the methyl-CpG-binding protein 2 gene (MECP2) are considered to be the candidate genes associated with SLE.
Genetic variants of TNFα, IL10, IL1β, CTLA4 and TGFβ1 modulate the indices of alcohol-induced liver injury in East Indian population.
Chowdhury et al., Calcutta, India. In Gene, 2012
identified polymorphic markers in TNFalpha, IL10, IL1beta and TGFbeta1 genes to be associated with alcoholic liver disease in the Bengali population
Association of cytotoxic T-lymphocyte associated antigen 4 gene polymorphism with type 1 diabetes mellitus: a meta-analysis.
Peng et al., Jixi, China. In Gene, 2012
CTLA-4 polymorphism contributes to the susceptibility of type 1 diabetes mellitus.
Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells.
Walker et al., Birmingham, United Kingdom. In J Immunol, 2012
CTLA-4-positive T cells, from transgenic mice that lack regulatory T (Treg) cells, are able to regulate the response of CTLA-4 negative T cells in cotransfer experiments.
Cutting edge: CTLA-4 on effector T cells inhibits in trans.
Allison et al., New York City, United States. In J Immunol, 2012
CTLA-4 on normal effector CD4-positive T cells completely abrogates the dramatically increased expansion normally experienced by their CTLA-4-deficient counterparts.
CD40, CD45 CTLA-4 levels are elevated in healthy older adults.
Terzioglu et al., Antalya, Turkey. In Clin Lab, 2011
CTLA-4 expression levels were higher in older subjects, with no difference in CD28 expression levels between younger/older individuals.
share on facebooktweetadd +1mail to friends